<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19087">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858414</url>
  </required_header>
  <id_info>
    <org_study_id>P/2014/223</org_study_id>
    <nct_id>NCT02858414</nct_id>
  </id_info>
  <brief_title>Exploratory Study of Cellular Reservoirs in Blood From HIV Infected Patients</brief_title>
  <acronym>EURECA</acronym>
  <official_title>Exploratory Study of Cellular Reservoirs in Blood From HIV Infected Patients: EURECA (ERANET to Unravel New Roads to Eradication and a Cure for AIDS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the impact of highly active antiretroviral therapy on the size of the
      latent viral reservoirs in resting CD4+ T cells and monocytes in HIV positive patients. The
      activation state of the cells will be assessed, by measuring the activation of Akt, to
      determine its influence on the size of the viral reservoirs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the integrated viral reservoir size</measure>
    <time_frame>day 1</time_frame>
    <description>Measure by Alu-PCR. Results are given in number of integrated proviral DNA copies per 1 million cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of the proviral reservoir size</measure>
    <time_frame>day 1</time_frame>
    <description>Measure by Total Proviral HIV DNA detection kit. Results are given in number of total proviral DNA copies per 1 million cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Akt activation</measure>
    <time_frame>day 1</time_frame>
    <description>Measure of Akt activation in live cells by flow cytometry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>blood sample</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>additional blood sample</intervention_name>
    <arm_group_label>blood sample</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected patients under Highly Active Anti-Retroviral Therapy (HAART) or Naïve
             from treatment

        Exclusion Criteria:

          -  Age limits

          -  Pregnancy

          -  Legal restrictions to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georges HERBEIN, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georges HERBEIN, MD-PhD</last_name>
    <email>g.herbein@chu-besancon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise ROBERT</last_name>
      <email>e1robert@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>July 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
